Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells

Clinical trials of imetelstat therapy have indicated that this telomerase inhibitor might have disease-modifying effects in a subset of patients with myelofibrosis (MF). The mechanism by which imetelstat induces such clinical responses has not been clearly elucidated. Using in vitro hematopoietic pr...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Wang, Xiaoli, Hu, Cing Siang, Petersen, Bruce, Qiu, Jiajing, Ye, Fei, Houldsworth, Jane, Eng, Kevin, Huang, Fei, Hoffman, Ronald
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2018
Soggetti:
Myeloid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6156882/
https://ncbi.nlm.nih.gov/pubmed/30242099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018022012
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi